Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Immunotherapy using checkpoint blockade (ICB) with antibodies such as anti-PD-1 has revolutionised the treatment of many cancers. Despite its use to treat COVID-19 patients and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, the effect of hydroxychloroquine (HCQ) o...

Full description

Bibliographic Details
Main Authors: Janna Krueger, Francois Santinon, Alexandra Kazanova, Mark E Issa, Bruno Larrivee, Richard Kremer, Catalin Milhalcioiu, Christopher E Rudd
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0251731

Internet

https://doi.org/10.1371/journal.pone.0251731

Similar Items